🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Oxford
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Oxford

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 675 Birmingham 472 Glasgow 439 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca20 AbbVie17 Hoffmann-La Roche16 Eli Lilly and Company15 Merck Sharp & Dohme LLC14
Site city
London2010 Manchester675 Birmingham472 Glasgow439 Cambridge416
All 426 cities
Target enrolment
to
361 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
London, Maidstone, Middlesbrough, Oxford, Sheffield, Birmingham, Bradford, Bristol
2024-09-11
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
AbbVie
Phase 2
540
Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff
2024-09-04
Active, closed
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772Coeliac Disease, Celiac Disease
Sanofi
Phase 2
229
Oxford, Sheffield
2024-08-29
Recruiting
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
NCT06565195Parkinson's Disease
Prevail Therapeutics
Phase 1
124
Southampton, Oxford
2024-08-27
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi
Phase 3
160
London, Inverness, Oxford
2024-08-21
Recruiting
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
NCT06600789Solid Malignancies
Carrick Therapeutics Limited
Phase 1/2
50
Manchester, Oxford, Sutton
2024-08-16
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals
Phase 3
550
Bath, Glasgow, Leicester, London, Manchester, Oxford, Wolverhampton
2024-08-13
Active, closed
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
NCT06313593Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
37
London, Oxford
2024-08-08
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Cambridge, Guildford, London, Manchester, Oxford, Swansea, Taunton, Truro
2024-08-01
Active, closed
Long-term Extension of GTX-102 in Angelman Syndrome
NCT06415344Angelman Syndrome
Ultragenyx Pharmaceutical Inc
Phase 3
255
Cambridge, London, Oxford
2024-07-31
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
Biohaven Therapeutics Ltd.
Phase 2
660
Swansea, Glasgow, Salford, Liverpool, Oxford, Cardiff, London, Newcastle upon Tyne
2024-07-30
Active, closed
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Bath, Birmingham, Bristol, Edinburgh, Guildford, London, Oxford, Plymouth
2024-07-22
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC
Phase 3
136
Edinburgh, London, Manchester, Oxford
2024-07-09
Recruiting
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
NCT06392386Generalized Myasthenia Gravis
argenx
Phase 2/3
12
Oxford
2024-06-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
Merck Sharp & Dohme LLC
Phase 3
1,200
Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, Oxford, Bristol
2024-06-05
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
Immunocore Ltd
Phase 3
680
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Oxford, Surrey Quays
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.
Phase 3
762
Aberdeen, Bristol, Leeds, London, Oxford, Plymouth, Port Talbot, Portsmouth
2024-05-24
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
Biohaven Therapeutics Ltd.
Phase 2/3
390
Swansea, Glasgow, Salford, Oxford, Cardiff, London, Newcastle upon Tyne
2024-05-13
Active, closed
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
NCT06294925Colitis, Ulcerative
Pfizer
Observational
360
Glasgow, Nottingham, Oxford, Edinburgh, Crumpsall, Kent, London, Newport
2024-05-08
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Exeter, Kent, London, Swansea, Nottingham, Oxford, Cardiff, Bristol
2024-04-16
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
Avalyn Pharma Inc.
Phase 2
375
Cottingham, Birmingham, Glenfield, London, Londonderry, Oxford, Exeter, Wolverhampton
2024-04-03
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
780
Cambridge, Northwood, London, Oxford, Newcastle upon Tyne
2024-04-03
Recruiting
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
NCT06435000Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Splice Bio
Observational
75
London, Leeds, Manchester, Oxford
2024-03-29
Recruiting
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
NCT06093672Polycythemia Vera
Italfarmaco
Phase 3
220
Belfast, Boston, London, Milton Keynes, Oxford, Southampton
2024-03-26
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
Chelsea, Oxford, Sutton
2024-03-25
Rows per page Showing 126–150 of 361
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/oxford

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.